Spero Therapeutics (NASDAQ:SPRO) Cut to In-Line at Evercore ISI

Evercore ISI downgraded shares of Spero Therapeutics (NASDAQ:SPRO) from an outperform rating to an in-line rating in a research note published on Friday, Marketbeat reports. Evercore ISI currently has $5.00 target price on the stock.

Other equities research analysts also recently issued research reports about the company. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Spero Therapeutics in a research note on Monday, December 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th.

Spero Therapeutics Trading Down 4.3 %

Shares of SPRO stock opened at $0.96 on Friday. Spero Therapeutics has a 12-month low of $0.95 and a 12-month high of $1.89. The company has a market cap of $52.07 million, a price-to-earnings ratio of 13.65 and a beta of 0.59. The stock has a 50 day simple moving average of $1.20 and a 200-day simple moving average of $1.29.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Spero Therapeutics stock. Renaissance Technologies LLC boosted its holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 975,952 shares of the company’s stock after acquiring an additional 121,492 shares during the period. Renaissance Technologies LLC owned 1.81% of Spero Therapeutics worth $1,269,000 as of its most recent filing with the Securities and Exchange Commission. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.